 ALX Oncology Holdings Inc NASDAQ: ALXO announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastroesophageal junction cancer GC. The new data were shared at the World Congress on Gastrointestinal Cancer. 